Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study

Introduction To address the burden of chronic obstructive pulmonary disease (COPD), the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends treatment according to classification of patients by symptom severity and exacerbation risk. This post hoc analysis of a previously reporte...

Full description

Saved in:
Bibliographic Details
Published in:Pulmonary therapy 2019-12, Vol.5 (2), p.191-200
Main Authors: Ray, Riju, Hahn, Beth, Stanford, Richard H., White, John, Essoi, Breanna, Hunter, Alyssa Goolsby
Format: Article
Language:English
Subjects:
Bronchodilator agents
Chronic obstructive pulmonary disease
Classification
COPD
Councils
Dyspnea
Exacerbation
Family Medicine
General Practice
GOLD
Hospitalization
Internal Medicine
LAMA monotherapy
Lung diseases
Medical research
Medicine
Medicine & Public Health
Original Research
Patient-reported outcome measures
Patients
Pharmacoeconomics and Health Outcomes
Pharmacotherapy
Pneumology/Respiratory System
Primary care
Quality of Life Research
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction To address the burden of chronic obstructive pulmonary disease (COPD), the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends treatment according to classification of patients by symptom severity and exacerbation risk. This post hoc analysis of a previously reported claims-linked, cross-sectional survey [study 205862 (HO-16-16642)] classified patients with COPD receiving long-acting muscarinic antagonist (LAMA) monotherapy based on the GOLD 2017 categories. Methods Eligible patients who were ≥ 40 years of age, with ≥ 2 claims with International Classification of Diseases-10th Revision-Clinical Modification COPD diagnosis codes J40–J44 ≥ 30 days apart during the 12-month baseline period, and ≥ 2 claims for LAMA monotherapy in the 6 months prior to identification, were identified using claims data from the Optum Research Database. Patients completed a survey assessing modified Medical Research Council (mMRC) Dyspnea Scale and COPD Assessment Test (CAT) scores and demographics; clinical characteristics were assessed from claims and survey data, while exacerbation history was assessed from claims data. GOLD symptom severity classifications were low (groups A and C) for patients with low scores on both the CAT and mMRC scales (scores of
ISSN:2364-1754
2364-1746
DOI:10.1007/s41030-019-00099-0